|Day Low/High||1.54 / 1.58|
|52 Wk Low/High||1.42 / 3.19|
Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective
RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer
Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences
Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer
Data Show RX-3117, Archexin® and Supinoxin™ Appear to be Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Show Early Evidence of Clinical Activity
Phase Ib Clinical Trial Successfully Completed and Maximum Tolerated Dose Determined
Important Clinical Progress in 2015 Highlights the Potential for Rexahn's Highly-Novel, Targeted Anti-Cancer Therapeutic Approach
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Evidence of Dose-Dependent Tumor Reduction Presented at Recent Medical Meetings
Additional Preclinical Data Continue to Support Evidence of the Anti-Cancer Effects of Supinoxin™ in Multiple Human Cancer Cell Models
Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Human Renal Cell Carcinoma
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.